Renalytix (Renalytix) EBIT : $-33.95 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Renalytix EBIT?

Renalytix's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-6.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-33.95 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Renalytix's annualized ROC % for the quarter that ended in Mar. 2024 was -137.58%. Renalytix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -5,376.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Renalytix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -70.96%.

Renalytix EBIT Historical Data

The historical data trend for Renalytix's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix EBIT Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

-42.34

-10.32

-35.79

-53.18

-42.22

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-10.92	-9.93	-8.89	-8.99	-6.14

Competitive Comparison of Renalytix's EBIT

For the Health Information Services subindustry, Renalytix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Renalytix's EV-to-EBIT falls into.

Renalytix EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.95 Mil.

Renalytix (NAS:RNLX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Renalytix's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-24.544 * ( 1 - 0% )	/	( (23.391	+	12.289)	/ 2 )
=	-24.544	/	17.84
=	-137.58 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	21.874	-	2.913	-	( 6.839	-	max(0, 13.897	-	9.467	+	6.839	))
=	23.391

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.769	-	5.128	-	( 4.704	-	max(0, 14.988	-	6.34	+	4.704	))
=	12.289

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Renalytix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-24.544	/	( ( (0.683 + max(-8.088, 0))	+	(0.23 + max(-8.825, 0)) )	/	2 )
=	-24.544	/	( ( 0.683	+	0.23 )	/	2 )
=	-24.544	/	0.4565
=	-5,376.56 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.37	+	0.512	+	0.746)	-	(2.913	+	0	+	7.803)
=	-8.088

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.554	+	0	+	1.082)	-	(5.128	+	0	+	5.333)
=	-8.825

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Renalytix's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-33.945	/	47.835
	=	-70.96 %

Renalytix EBIT Related Terms

Thank you for viewing the detailed overview of Renalytix's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (Renalytix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

RTNXF:USA RENX:UK 2O9A:Germany 2O9A:Germany 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Executives

Howard Jr Doran	officer: Chief Business Officer	C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie	director	85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain	officer: President	NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc.	10 percent owner	150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills	director, 10 percent owner	C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling	officer: Chief Financial Officer	C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc.	10 percent owner	ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount	10 percent owner	ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming	director, officer: Chief Technical Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough	director, officer: Chief Executive Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE